Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Samsung Electronics | Eli Lilly and Company | Duolingo | |
|---|---|---|---|
| Moat rating | narrow Samsung leads three of its four principal markets — Q1 2026 DRAM revenue share 38.5% ($37.32B, TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), Q1 2026 NAND share 31.6% ($13.51B, TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html), and #1 in Q2 2026 smartphones at 24% (Counterpoint via Android Authority, https://www.androidauthority.com/counterpoint-research-q2-2026-smartphone-shipment-report-3686931/) — but the moat is narrow, not wide: memory economics are violently cyclical (industry DRAM revenue swung +81% QoQ on contract-price spikes per the same TrendForce release), SK hynix holds the highest HBM bit-shipment mix among the top three (same release), and foundry trails TSMC 6.5% vs ~72% share (TrendForce data via TelecomLead, https://telecomlead.com/semiconductor/global-foundry-market-hits-record-47-95-bn-in-q1-2026-as-ai-chip-demand-drives-growth-tsmc-expands-share-to-72-126247). | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow Wide is ruled out by the company's own Item 1A, which concedes "low switching costs" and that "Low barriers to entry allow start-up companies with lower costs and less pressure for profitability to compete with us." It sits well above none because Q4 DAUs grew 30% to 52.7M, DAU/MAU rose to 39.6% from 34.7%, and marketing took only 12% of FY2025 revenue, though that ratio was flat versus FY2024 and gross margin fell to 72.2% from 72.8%. It stays narrow rather than eroding because Q1 FY2026 DAUs and paid subscribers each grew 21%. |
| Moat type | cost scale The durable advantage is manufacturing scale and capital intensity: the top three DRAM suppliers take roughly $8.97 of every $10 of industry revenue (Samsung 38.5% + SK hynix 28.8% + Micron 22.4% in Q1 2026 per TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), a structure sustained by multi-billion-dollar fab economics that has admitted no new large entrant in decades; Samsung is the largest-revenue producer in both DRAM and NAND (TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html). | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | intangibles ip The intangible is the consumer brand, not patents: Item 1 says "For many, Duolingo has become synonymous with language learning" and that growth is "organic, primarily driven by word-of-mouth and brand buzz," while the IP section discloses only "two patent applications." Switching costs are ruled out by the filing's own "low switching costs" caption. The data-scale support is the filing's own characterisation, and the brand is admittedly damageable: an April 2025 AI memo "may have contributed to unfavorable publicity, adverse impacts on the Company's brand and social media presence, and a deceleration in user growth." |
| Leadership | co leader Revenue leader in DRAM (38.5%) and NAND (31.6%) in Q1 2026 (TrendForce) and #1 in Q2 2026 smartphone shipments (Counterpoint), but not the leader where AI value concentrates: SK hynix has the highest HBM bit-shipment mix among the top three DRAM suppliers (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) and TSMC dominates foundry with ~72% share to Samsung's 6.5% (TrendForce via TelecomLead). | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | clear leader Leadership holds within consumer app-based language learning, anchored on one externally checkable claim in Item 1: the app "is also the top-grossing app globally in the Education category on both Google Play and the Apple App Store," with "over 250 total language courses to more than 130 million monthly active users" as of 2025-12-31. The broader "leading market position" claim is the filing's own characterisation, and no third-party share statistic appears anywhere in the 10-K, so a band is recorded and no percentage transcribed. The band does not extend to assessment, literacy, math, music, chess or offline learning, where the filing claims no position. |
| Pricing power | moderate Current pricing is extraordinary but cyclical, not structural: conventional DRAM contract prices rose roughly 93-98% QoQ in Q1 2026 (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) — shortage-driven commodity pricing that reverses in downcycles. The set-side shows the limit: Samsung's own MX (smartphone) division posted a KRW 0.7 trillion operating loss in Q2 2026 on elevated component costs (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | weak Every mechanism is cost, mix or volume, never price. FY2025 gross margin fell to 72.2% from 72.8% on "increased AI costs used in features like Video Call" and an advertising mix shift; the Q1 FY2026 gain to 73.0% came from "continued reductions in per-unit AI costs," with margin guided to about 71.0% in Q2 and "approximately 69.0% by Q4." The filing concedes it "may not be able to fully offset such higher costs through price increases." Subscription revenue rose 44% to $873.4 million "primarily due to an increase in the average number of paid subscribers," and the cap is self-imposed: "We intentionally do not put our learning content behind a paywall." |
| Summary | Samsung Electronics is the world's largest memory maker and a vertically integrated device company. In Q1 2026 it was #1 in DRAM (38.5% revenue share) and #1 in NAND (31.6%), and in Q2 2026 it retook #1 in global smartphones at 24% share. The AI-datacenter memory shortage produced record results: Q2 2026 company revenue of KRW 171.5 trillion and an all-time-high operating profit of KRW 89.5 trillion, with server memory reaching a record share of the sales mix and HBM4E samples shipped to major customers (Samsung Newsroom). The caveats that keep the moat narrow: the profit pool is a price cycle, not a structural annuity; SK hynix leads the highest-value HBM segment by bit-shipment mix; and Samsung Foundry, at 6.5% share versus TSMC's ~72%, remains a distant second in leading-edge logic despite expanding 2nm design wins. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Duolingo's moat is essentially one asset — a consumer brand strong enough that the filing claims people "search for the term 'Duolingo' much more often than 'learn Spanish'" — sitting on real but not defensive scale. It converts into economics through organic acquisition: sales and marketing took 12% of FY2025 revenue while Q4 DAUs grew 30% to 52.7 million and DAU/MAU rose to 39.6% from 34.7%. It is not wide, because the company supplies both disqualifiers itself: "low switching costs" and "Low barriers to entry allow start-up companies with lower costs and less pressure for profitability to compete with us." Width and pricing power diverge: Duolingo will not price against its own free product, grows subscription revenue by adding subscribers ($873.4 million, up 44%), and guides gross margin down to roughly 69% by Q4 FY2026 "as AI feature use expands in our products." |
| Chain position | Upstream supplier of DRAM/HBM and NAND to the AI datacenter buildout (server memory at a record share of its Q2 2026 sales mix; HBM4E samples shipped to major customers) and a contract foundry, while simultaneously a downstream device maker (Galaxy) that consumes its own components (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | A consumer AI application and net buyer of model inference. The filing ties its margin line directly to inference cost, attributing the FY2025 subscription gross-margin decline to "increased AI costs used in features like Video Call" and guiding margin to approximately 69.0% by Q4 FY2026 "as AI feature use expands," while the Q1 FY2026 beat came from "reductions in per-unit AI costs." |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm bearish Editorial prior, not backtested. |